08.04.2016 • NewsElaine BurridgechlorvinylsINOVYN

Inovyn Adopts Membrane Process for Swedish Chlorine Plant

Chlorvinyls producer Inovyn is to convert its mercury-based chlorine plant in Stenungsund, Sweden, to membrane technology as part of its commitment to phase out mercury cellroom production under upcoming European legislation.

Initial design and feasibility studies are underway with the project’s completion expected by the end of 2017.

The EU’s Industrial Emissions Directive requires chlor-alkali producers to implement Best Available Technology, or BAT, by Nov. 11, 2017.

According to industry association Euro Chlor, membrane technology now accounts for about 61% of Europe’s chlorine capacity, with the mercury process representing roughly 23% of production, or 2.75 million t/y chlorine.

Inovyn is already expanding its membrane chlorine cellroom at Antwerp/Lillo, which is due to go online in the fourth quarter of 2016. The company is also building a new potassium hydroxide (KOH) and chlorine plant at Antwerp/Lillo, Belgium.

Jean-Michel Mesland, Inovyn’s operations director, said the Stenungsund project would underpin the sustainability and competitiveness of the business in the long term.

The company said it was still evaluating options relating to its mercury cellroom at Martorell in Spain. The current lack of competitively priced raw materials, particularly energy, makes future investment in cellroom conversion at Martorell significantly less attractive, Inovyn said.

Inovyn is a 50:50 joint venture between Solvay and Ineos. Solvay said last month it would quit the venture in the second half of 2016.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.